Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Clinical trial NCT04631757 · UNKNOWN
Trial details
- NCT number
- NCT04631757
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-15
- Primary completion
- 2022-06-30
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.